Abstract:679 Germline mutations of the breast cancer associated gene 1 (BRCA1) have been identified in about 50% of familial breast cancer cases and about 90% of familial breast and ovarian cancers. BRCA1 mutation carriers have a 50 to 80% lifetime risk for developing breast cancer by age 70. Current screening and chemoprevention strategies are suboptimal and consequently some women who are BRCA1 gene carriers elect to prophylactically have their breasts and/or ovaries removed to reduce their risk. Moreover, current chemopreventative drugs often give adverse effects, primarily due to poor specificity of the compounds to mammary tumor tissues. Thus, there is an urgent need to develop safe and effective drugs for the chemoprevention and therapeutic treatment of breast cancer. In the past years, we have created a mouse model carrying a tissue specific disruption of BRCA1 in mammary epithelium. The mutant mice developed mammary tumors at 7-12 months of age. Our analysis revealed that the tumor progression is accompanied by extensive genetic instability and alteration of a number of oncogenes and tumor suppressor genes. Using this animal model and cell lines derived from mammary tumors, we have been studying effects of genistein, green tea, resveratrol, and Poly(ADP-ribose) polymerase (PARP1) inhibitors on BRCA1-associcated tumor formation in order to provide better understand and therapeutic options of BRCA1-assicated breast cancer. Our study indicated that both genistein and resveratrol inhibit growth of tumor cells in culture, in soft agar colony formation and in an allograft nude mouse model. Genistein treated BRCA1 mutant cells were highly polypoid and displayed extensive chromosome abnormalities. Western blot analysis revealed significant increase of CHK2 phosphorylation upon genistein treatment. These observations suggest that genistein induced activation of cell cycle inhibitors may cause cell cycle arrest and cell death, which account for the reduced growth of mutant cells upon the drug treatment. We found that the apoptosis induced by resveratrol in the tumors is accompanied by the activation of NF-kB pathway, and is also partially due to the activation of CHK2 in DNA damage response. Of note, we failed to detect any preventive or therapeutic effects of green tea in both allograft and BRCA1 conditional animals tested. The effectiveness of PARP-1 inhibitors also seemed more specific to BRCA1 mutant embryonic stem cells rather than BRCA1 mutant mammary tumor cells. These data, although promising, remain to be tested in human BRCA1 associated breast cancer cells. Our long-term goal is to decrease cancer risk of BRCA-mutation carriers and find a safe and effective therapeutic method to cure this disease.

Uterus Hyperplasia and Increased Carcinogen-Induced Tumorigenesis in Mice Carrying a Targeted Mutation of the Chk2 Phosphorylation Site in Brca1

Impaired Skin And Mammary Gland Development And Increased Gamma-Irradiation-Induced Tumorigenesis In Mice Carrying A Mutation Of S1152-Atm Phosphorylation Site In Brca1

Data from Impaired Skin and Mammary Gland Development and Increased γ-Irradiation–Induced Tumorigenesis in Mice Carrying a Mutation of S1152-ATM Phosphorylation Site in Brca1

Tumorigenesis as a consequence of genetic instability in Brca1 mutant mice

Atm-Chk2-P53 Activation Prevents Tumorigenesis At An Expense Of Organ Homeostasis Upon Brca1 Deficiency

Tumor formation inBrca1 conditional mutant mice

Hyperplasia and Spontaneous Tumor Development in the Gynecologic System in Mice Lacking the BRCA1-Δ11 Isoform

A Targeted Disruption of the Murine Brca1 Gene Causes Γ-Irradiation Hypersensitivity and Genetic Instability

Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer

Mutation of the Brca1 Sq-Cluster Results in Aberrant Mitosis, Reduced Homologous Recombination, and A Compensatory Increase in Non-Homologous End Joining

Absence Of Full-Length Brca1 Sensitizes Mice To Oxidative Stress And Carcinogen-Induced Tumorigenesis In The Esophagus And Forestomach

Mammary Tumorigenesis Following Transgenic Expression of a Dominant Negative CHK2 Mutant.

Chk2 Phosphorylation of BRCA1 Regulates DNA Double-Strand Break Repair

Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice

Mouse Models for BRCA1-associated Breast Cancer

Genetic Instability and Mammary Tumor Formation in Mice Carrying Mammary-Specific Disruption of Chk1 and P53

Mammary Tumors in Mice Conditionally Mutant for Brca1 Exhibit Gross Genomic Instability and Centrosome Amplification Yet Display a Recurring Distribution of Genomic Imbalances That is Similar to Human Breast Cancer

Tumor Formation in Mice with Conditional Inactivation of Brca1 in Epithelial Tissues.

Preclinical Evaluation of Radiation Therapy of BRCA1-associated Mammary Tumors Using a Mouse Model

Phosphorylation of Serine 1387 in Brca1 is Specifically Required for the Atm-Mediated S-Phase Checkpoint after Ionizing Irradiation

Chemoprevention and Therapeutic Treatment of Brca1 Associated Breast Cancer in Conditional Knockout Mice